Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) EBIT Margin (2020 - 2026)

Cytek Biosciences filings provide 6 years of EBIT Margin readings, the most recent being 9.0% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 1420.0% to 9.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 20.04%, a 980.0% decrease, with the full-year FY2025 number at 20.04%, down 980.0% from a year prior.
  • EBIT Margin hit 9.0% in Q4 2025 for Cytek Biosciences, up from 17.58% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 12.53% in Q2 2021 to a low of 36.12% in Q1 2025.
  • Median EBIT Margin over the past 5 years was 7.49% (2022), compared with a mean of 8.87%.
  • Biggest five-year swings in EBIT Margin: soared 1367bps in 2021 and later tumbled -2607bps in 2023.
  • Cytek Biosciences' EBIT Margin stood at 1.52% in 2021, then soared by 111bps to 0.17% in 2022, then tumbled by -235bps to 0.24% in 2023, then skyrocketed by 2308bps to 5.2% in 2024, then tumbled by -273bps to 9.0% in 2025.
  • The last three reported values for EBIT Margin were 9.0% (Q4 2025), 17.58% (Q3 2025), and 23.3% (Q2 2025) per Business Quant data.